NCT04305678View on ClinicalTrials.gov

Mepolizumab for Eosinophilic Fasciitis

PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

February 28, 2023

Primary Completion Date

February 15, 2023

Study Completion Date

February 15, 2023

Conditions

Eosinophilic Fasciitis

Interventions

DRUG

Mepolizumab

Mepolizumab (Nucala) 400 mg SC every 4 weeks x 24 weeks

Sponsors

Lead Sponsor

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

Mayo Clinic

OTHER

NCT04305678 - Mepolizumab for Eosinophilic Fasciitis | Biotech Hunter | Biotech Hunter